Clinical research

1. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma
   Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW, Yoon JH. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology. 2015 Jun;148(7):1383-91.e6. doi: 10.1053/j.gastro.2015.02.055. Epub 2015 Mar 4. PMID: 25747273.
2. Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea
   Kong DS, Nam DH, Kang SH, Lee JW, Chang JH, Kim JH, Lim YJ, Koh YC, Chung YG, Kim JM, Kim CH. Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea. Oncotarget. 2017 Jan 24;8(4):7003-7013. doi: 10.18632/oncotarget.12273. PMID: 27690294; PMCID: PMC5351686.
3. Phase II/III Study of Radiofrequency Ablation Combined with Cytokine-Induced Killer Cells Treating Colorectal Liver Metastases
   Li X, Dai X, Shi L, Jiang Y, Chen X, Chen L, Zhao J, Qiang W, Wu J, Ji M, Jiang J, Wu C. Phase II/III Study of Radiofrequency Ablation Combined with Cytokine-Induced Killer Cells Treating Colorectal Liver Metastases. Cell Physiol Biochem. 2016;40(1-2):137-145. doi: 10.1159/000452531. Epub 2016 Nov 18. PMID: 27855365.
4. Randomized controlled phase III trial of adjuvant chemoimmunotherapy with activated cytotoxic T cells and dendritic cells from regional lymph nodes of patients with lung cancer
   Kimura H, Matsui Y, Ishikawa A, Nakajima T, Iizasa T. Randomized controlled phase III trial of adjuvant chemoimmunotherapy with activated cytotoxic T cells and dendritic cells from regional lymph nodes of patients with lung cancer. Cancer Immunol Immunother. 2018 Aug;67(8):1231-1238. doi: 10.1007/s00262-018-2180-6. Epub 2018 May 31. PMID: 29855695; PMCID: PMC6097784.
5. Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer
   Kimura H, Matsui Y, Ishikawa A, Nakajima T, Yoshino M, Sakairi Y. Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer. Cancer Immunol Immunother. 2015 Jan;64(1):51-9. doi: 10.1007/s00262-014-1613-0. Epub 2014 Sep 28. PMID: 25262164; PMCID: PMC4282697.
6. Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies
   Schmeel FC, Schmeel LC, Gast SM, Schmidt-Wolf IG. Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies. Int J Mol Sci. 2014 Aug 21;15(8):14632-48. doi: 10.3390/ijms150814632. PMID: 25196601; PMCID: PMC4159872.
7. Clinical studies applying cytokine-induced killer cells for the treatment of gastrointestinal tumors
   Jäkel CE, Vogt A, Gonzalez-Carmona MA, Schmidt-Wolf IG. Clinical studies applying cytokine-induced killer cells for the treatment of gastrointestinal tumors. J Immunol Res. 2014;2014:897214. doi: 10.1155/2014/897214. Epub 2014 Jan 16. PMID: 24741629; PMCID: PMC3987941.
8. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC)
   Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2011 Feb;137(2):305-10. doi: 10.1007/s00432-010-0887-7. Epub 2010 Apr 21. PMID: 20407789.
9. New adoptive immunotherapy strategies for solid tumours with CIK cells
   Thanendrarajan S, Kim Y, Schmidt-Wolf I. New adoptive immunotherapy strategies for solid tumours with CIK cells. Expert Opin Biol Ther. 2012 May;12(5):565-72. doi: 10.1517/14712598.2012.668879. Epub 2012 Mar 24. PMID: 22444075.
10. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma
    Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer. 1999 Nov;81(6):1009-16. doi: 10.1038/sj.bjc.6690800. PMID: 10576658; PMCID: PMC2362953.
11. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma
    Märten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, Caspari R, Flieger D, Hanfland P, Von Ruecker A, Eis-Hübinger AM, Müller S, Schwaner I, Lohmann U, Heylmann G, Sauerbruch T, Schmidt-Wolf IG. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther. 2003 Mar 20;14(5):483-94. doi: 10.1089/104303403321467243. PMID: 12691613.
12. An Alternative Source for Allogeneic CAR T Cells With a High Safety Profile
    Wu X, Schmidt-Wolf IGH. An Alternative Source for Allogeneic CAR T Cells With a High Safety Profile. Front Immunol. 2022 May 23;13:913123. doi: 10.3389/fimmu.2022.913123. PMID: 35677035; PMCID: PMC9170073.
13. Generation of dendritic cell-based vaccines for cancer therapy
    Reinhard G, Märten A, Kiske SM, Feil F, Bieber T, Schmidt-Wolf IG. Generation of dendritic cell-based vaccines for cancer therapy. Br J Cancer. 2002 May 20;86(10):1529-33. doi: 10.1038/sj.bjc.6600316. PMID: 12085199; PMCID: PMC2746586.
14. Interleukin-7 gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma
    Schmidt-Wolf IG, Huhn D, Neubauer A, Wittig B. Interleukin-7 gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma. Hum Gene Ther. 1994 Sep;5(9):1161-8. doi: 10.1089/hum.1994.5.9-1161. PMID: 7530496.